A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
After six years Bellicum admits it’s not ready for prime time
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
Veklury boosts Gilead, yet disappoints too
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.
Lilly swerves the worst case for its Covid-19 antibody
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Healthineers collaboration aims to link antibodies to immunity
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
